JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MARZO, M. E.
Right arrow Articles by CODINA, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MARZO, M. E.
Right arrow Articles by CODINA, A.
J Neurol Neurosurg Psychiatry 1998;65:604 ( October )

Letters to the editor

Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-alpha

The first 150 words of the full text of this article appear below.

Interferon-alpha (IFN-alpha ) is widely used for the treatment of chronic viral hepatitis. There have been some reports concerning the development of autoimmune diseases, particularly thyroid disease, in patients under treatment with IFN.1 Disorders including autoimmune haemolytic anaemia, pernicious anaemia, thrombocytopenic purpura, systemic lupus erythematosus, Raynaud's disease, parotiditis, and epididymitis have been reported. Some neurological problems have also been described2; although most such adverse events have involved the CNS, several cases of peripheral nervous system involvement have been reported---namely, axonal polyneuropathy,3 neuralgic amyotrophy, multiple mononeuropathies, and myasthenia gravis.4 On the other hand, some authors have reported that IFN-alpha may be an effective alternative therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are refractory to conventional treatments.5 Two trials using IFN-alpha and IFN-beta on patients with CIDP are currently in progress. We describe one patient who developed CIDP during IFN-alpha treatment.

A 29 year old man who had . . . [Full text of this article]


This article has been cited by other articles:


Home page
 NeurologyHome page
C. Briani, L. Chemello, G. Zara, M. Ermani, E. Bernardinello, S. Ruggero, E. Toffanin, A. Gatta, L. Battistin, and L. Cavalletto
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV.
Neurology, September 12, 2006; 67(5): 781 - 785.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Ekstein, E. Linetsky, O. Abramsky, and D. Karussis
Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis
Neurology, August 9, 2005; 65(3): 456 - 458.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Koller, B. C. Kieseier, S. Jander, and H.-P. Hartung
Chronic Inflammatory Demyelinating Polyneuropathy
N. Engl. J. Med., March 31, 2005; 352(13): 1343 - 1356.
[Full Text] [PDF]

Home page
 NeurologyHome page
T.J. Loher, J.K. Krauss, J.-M. Burgunder, E. Taub, and J. Siegfried
Chronic thalamic stimulation for treatment of dystonic paroxysmal nonkinesigenic dyskinesia
Neurology, January 23, 2001; 56(2): 268 - 270.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. Bennay, M. Gernert, and A. Richter
Spontaneous Remission of Paroxysmal Dystonia Coincides with Normalization of Entopeduncular Activity in dtsz Mutants
J. Neurosci., July 1, 2001; 21(13): RC153 - RC153.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1998 by the BMJ Publishing Group Ltd.